id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-341650-f8orw6ro	Li, Hailan	Regarding “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial”	2020-09-17		.txt	text/plain	511	30	64	title: Regarding "Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial" Regarding ''Ruxolitinib in Q 1 treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, singleblind, randomized controlled trial'' Q 2 To the Editor: We read with great interest the article titled ''Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial'' by Cao et al. 1 The study, which finally included 41 patients, evaluated the efficacy and safety of ruxolitinib for severe COVID-19 cases. First, the duration from illness onset to randomization, 22 days for the control group and 20 days for the ruxolitinib group, was not appropriate because according to literature reports, 2-4 the course (from illness onset to discharge) of severe patients was about 27 to 30 days. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, singleblind, randomized controlled trial Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study	./cache/cord-341650-f8orw6ro.txt	./txt/cord-341650-f8orw6ro.txt